Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

NCT07014917 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
CLL Variant

Interventions

DRUG: Venetoclax
DRUG: Acalabrutinib
DRUG: Venetoclax
DRUG: Acalabrutinib

Sponsor

Zulfa Omer